QIAGEN (NYSE:QGEN) Price Target Raised to $53.00

by · The Markets Daily

QIAGEN (NYSE:QGEN – Free Report) had its price objective hoisted by Bank of America from $50.00 to $53.00 in a research report sent to investors on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other analysts have also recently issued reports on the company. Redburn Atlantic cut QIAGEN from a “buy” rating to a “neutral” rating in a research report on Friday, April 4th. Robert W. Baird raised their price target on QIAGEN from $42.00 to $43.00 and gave the company a “neutral” rating in a report on Monday, April 21st. Barclays started coverage on shares of QIAGEN in a report on Tuesday, June 24th. They issued an “overweight” rating and a $55.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of QIAGEN from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 15th. Seven investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $49.40.

Check Out Our Latest Report on QGEN

QIAGEN Stock Down 0.6%

NYSE:QGEN opened at $47.76 on Thursday. QIAGEN has a twelve month low of $37.63 and a twelve month high of $49.30. The firm has a market capitalization of $10.62 billion, a price-to-earnings ratio of 119.76, a price-to-earnings-growth ratio of 2.44 and a beta of 0.67. The company has a quick ratio of 2.83, a current ratio of 3.37 and a debt-to-equity ratio of 0.40. The stock’s 50 day moving average price is $44.21 and its two-hundred day moving average price is $42.51.

QIAGEN (NYSE:QGEN – Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.05. QIAGEN had a net margin of 4.68% and a return on equity of 14.61%. The business had revenue of $483.46 million during the quarter, compared to analysts’ expectations of $465.66 million. During the same period last year, the business earned $0.44 earnings per share. The firm’s revenue was up 5.2% on a year-over-year basis. Equities research analysts expect that QIAGEN will post 2.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On QIAGEN

A number of hedge funds have recently bought and sold shares of the business. Envestnet Portfolio Solutions Inc. grew its position in shares of QIAGEN by 3.6% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 9,816 shares of the company’s stock worth $438,000 after purchasing an additional 341 shares in the last quarter. Pitcairn Co. boosted its stake in shares of QIAGEN by 5.3% in the fourth quarter. Pitcairn Co. now owns 6,996 shares of the company’s stock valued at $312,000 after buying an additional 354 shares during the period. Exchange Traded Concepts LLC grew its position in QIAGEN by 2.3% during the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company’s stock worth $716,000 after buying an additional 395 shares in the last quarter. Headlands Technologies LLC grew its position in QIAGEN by 2.0% during the fourth quarter. Headlands Technologies LLC now owns 19,823 shares of the company’s stock worth $883,000 after buying an additional 397 shares in the last quarter. Finally, Moors & Cabot Inc. increased its stake in QIAGEN by 0.5% during the 4th quarter. Moors & Cabot Inc. now owns 86,474 shares of the company’s stock worth $3,851,000 after acquiring an additional 426 shares during the period. 70.00% of the stock is owned by institutional investors.

QIAGEN Company Profile

(Get Free Report)

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

See Also